If you could vote on Brexit now which option would you choose?

The US agrees to buy additional doses of GSK-Vir's Covid-19 antibody

The US Government has entered an agreement to procure 600,000 additional doses of GlaxoSmithKline (GSK) and Vir Biotechnology’s antibody sotrovimab for early Covid-19 treatment, according to an announcement. An investigational monoclonal antibody, sotrovimab attaches to an epitope on SARS-CoV-2, which is shared with SARS-CoV-1. In May last year, the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to single intravenous (IV) dose of sotrovimab for mild to moderate Covid-19 treatment. The SARS-CoV-2 neutralising antibody is indicated under EUA for use in adult and paediatric Covid-19 patients aged 12 years and above who are at great disease progression risk, including hospital admission or mortality. GSK noted that the additional doses will be supplied throughout the first quarter of this year.

Pharmaceutical Technology - January 12, 2022

View the full story here: https://www.pharmaceutical-technology.com/news/us-gsk-vir-antibody-doses/